Literature DB >> 28814218

Diagnosis and management of pancreatic exocrine insufficiency.

Mehrdad Nikfarjam1, Jeremy S Wilson2, Ross C Smith3.   

Abstract

INTRODUCTION: In 2015, the Australasian Pancreatic Club (APC) published the Australasian guidelines for the management of pancreatic exocrine insufficiency (http://pancreas.org.au/2016/01/pancreatic-exocrine-insufficiency-guidelines). Pancreatic exocrine insufficiency (PEI) occurs when normal digestion cannot be sustained due to insufficient pancreatic digestive enzyme activity. This may be related to a breakdown, at any point, in the pancreatic digestive chain: pancreatic stimulation; synthesis, release or transportation of pancreatic enzymes; or synchronisation of secretions to mix with ingested food. Main recommendations: The guidelines provide advice on diagnosis and management of PEI, noting the following: A high prevalence of PEI is seen in certain diseases and conditions, such as cystic fibrosis, acute and chronic pancreatitis, pancreatic cancer and pancreatic surgery. The main symptoms of PEI are steatorrhoea or diarrhoea, abdominal pain, bloating and weight loss. These symptoms are non-specific and often go undetected and untreated. PEI diagnosis is predominantly based on clinical findings and the presence of underlying disease. The likelihood of PEI in suspected patients has been categorised into three groups: definite, possible and unlikely. If left untreated, PEI may lead to complications related to fat malabsorption and malnutrition, and have an impact on quality of life. Pancreatic enzyme replacement therapy (PERT) remains the mainstay of PEI treatment with the recommended adult initial enzyme dose being 25 000-40 000 units of lipase per meal, titrating up to a maximum of 75 000-80 000 units of lipase per meal. Adjunct acid-suppressing therapy may be useful when patients still experience symptoms of PEI on high dose PERT. Nutritional management by an experienced dietitian is essential. Changes in management as a result of these guidelines: These are the first guidelines to classify PEI as being definite, possible or unlikely, and provide a diagnostic algorithm to facilitate the early diagnosis of PEI and appropriate use of PERT.

Entities:  

Keywords:  Biochemistry; Malabsorption syndromes; Pancreatic diseases

Mesh:

Year:  2017        PMID: 28814218     DOI: 10.5694/mja16.00851

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  7 in total

Review 1.  Pancreatic Exocrine Insufficiency as a Complication of Gastrointestinal Surgery and the Impact of Pancreatic Enzyme Replacement Therapy.

Authors:  Adarsh Chaudhary; J Enrique Domínguez-Muñoz; Peter Layer; Markus M Lerch
Journal:  Dig Dis       Date:  2019-08-16       Impact factor: 2.404

2.  The investigation and management of pancreatic exocrine insufficiency: A retrospective cohort study.

Authors:  Benjamin M Shandro; Jennifer Ritehnia; Joshua Chen; Rani Nagarajah; Andrew Poullis
Journal:  Clin Med (Lond)       Date:  2020-11       Impact factor: 2.659

Review 3.  State of the Art in Exocrine Pancreatic Insufficiency.

Authors:  Carmelo Diéguez-Castillo; Cristina Jiménez-Luna; Jose Prados; José Luis Martín-Ruiz; Octavio Caba
Journal:  Medicina (Kaunas)       Date:  2020-10-07       Impact factor: 2.430

4.  Multidisciplinary consensus statement on the clinical management of patients with pancreatic cancer.

Authors:  E Martin-Perez; J E Domínguez-Muñoz; F Botella-Romero; L Cerezo; F Matute Teresa; T Serrano; R Vera
Journal:  Clin Transl Oncol       Date:  2020-04-21       Impact factor: 3.405

5.  Complications of chronic pancreatitis prior to and following surgical treatment: A proposal for classification.

Authors:  Marko Murruste; Ülle Kirsimägi; Karri Kase; Tatjana Veršinina; Peep Talving; Urmas Lepner
Journal:  World J Clin Cases       Date:  2022-08-06       Impact factor: 1.534

6.  Diarrhea due to SARS-CoV-2-Related Exocrine Pancreatic Insufficiency.

Authors:  Harish K Patel; Jasbir Makker; Ahemd Alemam; Sridhar Chilimuri
Journal:  Case Rep Gastrointest Med       Date:  2021-05-21

7.  Intestinal Absorption of Lipids Using a Pancreatic Enzyme-Free Nutritional Supplement in Patients with Cystic Fibrosis: A Randomized, Double-Blind, Crossover Pilot Trial.

Authors:  Tara L Barto; Clarissa F Morency; Nicoline Schaap; Ami B Patel; Daniel J Monticello
Journal:  Nutrients       Date:  2022-02-05       Impact factor: 5.717

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.